When Is a Condition Considered in Remission?
Remission is defined as the complete absence of signs and symptoms of significant inflammatory disease activity, assessed using validated disease activity measures, and sustained for a minimum specified duration that varies by condition.
Core Principles of Remission
The definition of remission depends critically on three components that must be explicitly stated 1:
1. Complete Absence of Active Disease
- Not "partial remission," "improvement," or "disease control" - these terms should be avoided 1
- Must demonstrate no clinically detectable inflammatory activity 2, 3
- Applies to all disease manifestations, not just the primary features (e.g., in vasculitis, includes both vasculitic and granulomatous manifestations) 1
2. Validated Measurement Tools
Remission must be documented systematically using disease-specific validated instruments:
For Rheumatoid Arthritis 2, 3, 4:
- Tender joint count ≤1
- Swollen joint count ≤1
- C-reactive protein ≤1 mg/dL
- Patient global assessment ≤1 (on 0-10 scale)
- OR Simplified Disease Activity Index ≤3.3
For Vasculitis (AAV) 1:
- Birmingham Vasculitis Activity Score (BVAS) = 0
- Must be on stable low-dose glucocorticoids (≤7.5 mg/day prednisone equivalent)
For Spondyloarthritis 5:
- Clinical remission defined as absence of significant musculoskeletal disease activity
- Minimal disease activity (MDA) is an acceptable alternative when complete remission cannot be achieved
3. Minimum Duration Requirement
Critical timing thresholds 1, 6:
- Sustained remission: 6-12 months of continuous inactive disease 6, 7
- For vasculitis: minimum duration must be specified in each protocol, as relapse risk is highest within first 6 months 1
- For rheumatoid arthritis: 6 continuous months on medication defines "clinical remission on medication"; 12 months off all medications defines "clinical remission off medication" 8
Medication Status During Remission
Remission does NOT require complete drug withdrawal 1:
- Patients can be in remission while receiving maintenance immunosuppressive therapy
- The specific medications, dosages, and duration must be documented
- For vasculitis: glucocorticoids ≤7.5 mg/day are acceptable 1
- This distinguishes "remission on medication" from "remission off medication" 8
Disease-Specific Considerations
Inflammatory Conditions
- Must include absence of inflammatory biomarkers when applicable 1
- For conditions with validated biomarkers, these should be included (e.g., undetectable or low levels) 1
Chronic Pain
- Sustained pain score ≤3.0 cm on 10 cm VAS for ≥6 months 9
- Must correlate with minimal disability and high patient satisfaction
Type 2 Inflammatory Diseases
- Requires multidimensional evaluation: clinical symptoms, inflammatory markers, and histologic criteria 10
- For chronic rhinosinusitis: ≥12 months of symptom absence, no rescue medications, and recovery of smell function 10
Common Pitfalls to Avoid
Do not accept "low disease activity" as remission - while low disease activity is an acceptable alternative therapeutic goal in long-standing disease 2, it is not remission 5
Do not use imprecise terminology - avoid "partial remission," "stabilization," "improvement," or "disease control" 1
Do not rely solely on patient-reported outcomes - objective measures (joint counts, inflammatory markers, validated scores) are mandatory 2, 3, 4
Do not declare remission too early - the probability of relapse is particularly high within the first 6 months, so minimum duration criteria are essential 1
Do not ignore ongoing treatment - always document the type, dose, and duration of any immunosuppressive therapy at the time remission is declared 1
Monitoring During Remission
Once remission is achieved 2:
- Disease activity measures should be obtained every 6 months for patients in sustained remission
- More frequent monitoring (monthly) is required for patients with high/moderate disease activity
- The treatment target (remission) should be maintained throughout the remaining course of disease 2